INT148271

Context Info Confidence 0.37 First Reported 2003 Last Reported 2010 Negated 2 Speculated 0 Reported most in Body Documents 10 Total Number 10 Disease Relevance 5.89 Pain Relevance 0.86

cytoskeleton (SGCA) cytoplasm (SGCA)

SGCA (Homo sapiens)

Pain Link Frequency Relevance Heat Pain 92 99.46 Post herpetic neuralgia 102 94.72 ischemia 5 94.08 Inflammation 16 91.84 Shingles 5 43.20 Antihistamine 1 41.60 Calcium channel 1 40.16 fluoxetine 1 29.44 Glutamate 20 5.00 nMDA receptor 13 5.00

Disease Link Frequency Relevance Heat Disease 409 99.68 Dementia 55 99.56 Pain 95 99.46 Cognitive Disorder 142 97.88 Herpes Zoster 155 97.72 Neuralgia 102 94.72 Cv Unclassified Under Development 4 94.08 Neurological Disease 3 93.08 Aging 8 92.72 Keloid Scars 2 92.20

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

During follow up, patients were asked about pain, stiffness, weakness of the calf, footwear restrictions, occupation and level of activity before and after injury (Tegner score), influence of injury on ADL activities and satisfaction with treatment.

Regulation (influence) of ADL

1) Confidence 0.37 Published 2008 Journal Arch Orthop Trauma Surg Section Body Doc Link 18057945 Disease Relevance 0.07 Pain Relevance 0

The proportion of people affected with ADL episodes in the present study (5.4%) is similar to that reported from another bancroftian filarial endemic community from South India (5.3%) [6].

Regulation (affected) of ADL

2) Confidence 0.28 Published 2005 Journal BMC Public Health Section Body Doc Link PMC1156912 Disease Relevance 0.70 Pain Relevance 0.17

In the second analysis a responder was less strictly defined as ‘each patient that improved or had no deterioration on the CIBIC-Plus and who had improved or had no deterioration on either the ADCS-ADL or the SIB’.

Neg (no) Regulation (deterioration) of ADCS-ADL

3) Confidence 0.03 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695219 Disease Relevance 0.19 Pain Relevance 0

The primary efficacy measures were the change from baseline on the SIB (Schmitt et al 1997) and the ADCS-ADL19 (Galasko et al 2005).

Regulation (change) of ADCS-ADL19

4) Confidence 0.03 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654628 Disease Relevance 0.22 Pain Relevance 0

The improvement was correlated with the PSI risk severity (p = 0.03) as the largest change in ADL was noted in Class V.

Regulation (change) of ADL

5) Confidence 0.01 Published 2006 Journal BMC Geriatr Section Body Doc Link PMC1557854 Disease Relevance 0 Pain Relevance 0

From days 30 to 60, the absolute change in ADL was the smallest in Class II but an improvement in function status was still observed in the remaining risk classes.

Regulation (change) of ADL

6) Confidence 0.01 Published 2006 Journal BMC Geriatr Section Body Doc Link PMC1557854 Disease Relevance 0 Pain Relevance 0

Complex tasks that involve executive functioning – such as the management of finances, using household appliances, and performing household chores – are often impaired early in the disease, whereas basic ADL – such as grooming and hygiene, toileting, and feeding – are not affected until the dementia is more advanced.

Neg (not) Regulation (affected) of ADL associated with dementia and disease

7) Confidence 0.01 Published 2003 Journal Ann Gen Hosp Psychiatry Section Body Doc Link PMC149431 Disease Relevance 1.22 Pain Relevance 0

The primary outcome measures were changes on the SIB and ADCS-ADL-19 from baseline to week 24.

Regulation (changes) of ADCS-ADL-19

8) Confidence 0.01 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2773287 Disease Relevance 0.48 Pain Relevance 0.05

The PDS is a second-choice test that measures the ADL and includes an assessment of the caregiver’s quality of life.

Regulation (measures) of ADL

9) Confidence 0.00 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2684084 Disease Relevance 0.75 Pain Relevance 0

Pain is the major symptom that affects the QoL and ADL of patients and is usually present across all phases of HZ disease.

Regulation (affects) of ADL associated with pain, herpes zoster and disease

10) Confidence 0.00 Published 2010 Journal BMC Med Section Body Doc Link PMC2905321 Disease Relevance 2.27 Pain Relevance 0.64

General Comments

This test has worked.